126 related articles for article (PubMed ID: 36350459)
1. Prognostic Value of Preoperative Serological Biomarkers in Patients Undergoing Curative-Intent Cytoreductive Surgery for Colorectal Cancer Peritoneal Metastases.
El Asmar A; Delcourt M; Kamden L; Khaled C; Bohlok A; Moreau M; Sclafani F; Donckier V; Liberale G
Ann Surg Oncol; 2023 Mar; 30(3):1863-1869. PubMed ID: 36350459
[TBL] [Abstract][Full Text] [Related]
2. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis from colorectal cancer: The prognostic impact of baseline neutrophil-lymphocyte, platelet-lymphocyte and lymphocyte-monocyte ratios.
Zager Y; Hoffman A; Dreznik Y; Jacoby H; Cordoba M; Horesh N; Nevler A; Gutman M; Berger Y
Surg Oncol; 2020 Dec; 35():321-327. PubMed ID: 32977104
[TBL] [Abstract][Full Text] [Related]
3. Preoperative platelet-lymphocyte ratio is an independent prognostic marker and superior to carcinoembryonic antigen in colorectal peritoneal carcinomatosis patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Bong TSH; Tan GHC; Chia C; Soo KC; Teo MCC
Int J Clin Oncol; 2017 Jun; 22(3):511-518. PubMed ID: 28138878
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of preoperative serological biomarkers in patients undergoing cytoreductive surgery for ovarian cancer peritoneal metastases.
Khaled C; El Asmar A; Raisi O; Moreau M; Polastro L; Veys I; Pop FC; Donckier V; Liberale G
Pleura Peritoneum; 2023 Sep; 8(3):133-138. PubMed ID: 37662604
[TBL] [Abstract][Full Text] [Related]
5. [Construction and evaluation of a nomogram for predicting the prognosis of patients with colorectal cancer with peritoneal carcinomatosis treated with cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy].
An SL; Ji ZH; Li XB; Liu G; Zhang YB; Gao C; Zhang K; Zhang XJ; Yan GJ; Yan LJ; Li Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2023 May; 26(5):434-441. PubMed ID: 37217351
[No Abstract] [Full Text] [Related]
6. Peritoneal carcinomatosis index predicts survival in colorectal patients undergoing HIPEC using oxaliplatin: a retrospective single-arm cohort study.
Burnett A; Lecompte MA; Trabulsi N; Dubé P; Gervais MK; Trilling B; Cloutier AS; Sideris L
World J Surg Oncol; 2019 May; 17(1):83. PubMed ID: 31092250
[TBL] [Abstract][Full Text] [Related]
7. Impact of Synchronous Versus Metachronous Onset of Colorectal Peritoneal Metastases on Survival Outcomes After Cytoreductive Surgery (CRS) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC): A Multicenter, Retrospective, Observational Study.
Hentzen JEKR; Rovers KP; Kuipers H; van der Plas WY; Been LB; Hoogwater FJH; van Ginkel RJ; Hemmer PHJ; van Dam GM; de Hingh IHJT; Kruijff S
Ann Surg Oncol; 2019 Jul; 26(7):2210-2221. PubMed ID: 30877495
[TBL] [Abstract][Full Text] [Related]
8. Direct surgery with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for patients with colorectal peritoneal metastases.
Ljunggren M; Nordenvall C; Palmer G
Eur J Surg Oncol; 2021 Nov; 47(11):2865-2872. PubMed ID: 34116900
[TBL] [Abstract][Full Text] [Related]
9. In Patients Undergoing CRS/HIPEC for Colorectal Adenocarcinoma with Peritoneal Metastases, Presence of Ascites on Computed Tomography Imaging is not a Prognostic Marker for Survival.
Said I; Ubink I; Ewalds RSG; Arkesteijn JGT; Verheul HMW; de Wilt JHW; Dekker HM; Bremers AJA; de Reuver PR
Ann Surg Oncol; 2022 Aug; 29(8):5256-5262. PubMed ID: 35430666
[TBL] [Abstract][Full Text] [Related]
10. Treatment of Isolated Peritoneal Recurrences in Patients with Colorectal Peritoneal Metastases Previously Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
van Eden WJ; Elekonawo FMK; Starremans BJ; Kok NFM; Bremers AJA; de Wilt JHW; Aalbers AGJ
Ann Surg Oncol; 2018 Jul; 25(7):1992-2001. PubMed ID: 29671139
[TBL] [Abstract][Full Text] [Related]
11. Peritoneal cancer index (PCI) based patient selecting strategy for complete cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy in gastric cancer with peritoneal metastasis: A single-center retrospective analysis of 125 patients.
Ji ZH; Yu Y; Liu G; Zhang YB; An SL; Li B; Li XB; Yan GJ; Li Y
Eur J Surg Oncol; 2021 Jun; 47(6):1411-1419. PubMed ID: 33293213
[TBL] [Abstract][Full Text] [Related]
12. [Efficacy of 1 384 cases of peritoneal carcinomatosis underwent cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy].
Yu Y; Li XB; Lin YL; Ma R; Ji ZH; Zhang YB; An SL; Liu G; Yang XJ; Li Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Mar; 24(3):230-239. PubMed ID: 34645167
[No Abstract] [Full Text] [Related]
13. Primary Tumor Sidedness is Predictive of Survival in Colon Cancer Patients Treated with Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy: A US HIPEC Collaborative Study.
Kotha NV; Baumgartner JM; Veerapong J; Cloyd JM; Ahmed A; Grotz TE; Leiting JL; Fournier K; Lee AJ; Dineen SP; Dessureault S; Clarke C; Mogal H; Zaidi MY; Russell MC; Patel SH; Sussman JJ; Dhar V; Lambert LA; Hendrix RJ; Abbott DE; Pokrzywa C; Lafaro K; Lee B; Greer JB; Fackche N; Lowy AM; Kelly KJ
Ann Surg Oncol; 2019 Jul; 26(7):2234-2240. PubMed ID: 31016486
[TBL] [Abstract][Full Text] [Related]
14. Colic and rectal tumors with peritoneal metastases treated with cytoreductive surgery and HIPEC: One homogeneous condition or two different diseases? A systematic review and meta-analysis.
Tonello M; Sommariva A; Pirozzolo G; Mattara G; Pilati P
Eur J Surg Oncol; 2019 Nov; 45(11):2003-2008. PubMed ID: 31217079
[TBL] [Abstract][Full Text] [Related]
15. Outcomes following synchronous liver resection, cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal liver and peritoneal metastases: A bi-institutional study.
Flood MP; Waters PS; Kelly ME; Shields C; Conneely J; Ramsay R; Michael M; Loveday B; Warrier SK; Mulsow J; Heriot AG
Surg Oncol; 2021 Jun; 37():101553. PubMed ID: 33839444
[TBL] [Abstract][Full Text] [Related]
16. Survival of patients with colorectal peritoneal metastases is affected by treatment disparities among hospitals of diagnosis: A nationwide population-based study.
Rovers KP; Simkens GA; Vissers PA; Lemmens VE; Verwaal VJ; Bremers AJ; Wiezer MJ; Burger JW; Hemmer PH; Boot H; van Grevenstein WM; Meijerink WJ; Aalbers AG; Punt CJ; Tanis PJ; de Hingh IH;
Eur J Cancer; 2017 Apr; 75():132-140. PubMed ID: 28222307
[TBL] [Abstract][Full Text] [Related]
17. Peritoneal carcinomatosis arising from rectal or colonic adenocarcinoma treated with cytoreductive surgery (CRS) hyperthermic intraperitoneal chemotherapy (HIPEC): two different diseases.
Tonello M; Ortega-Perez G; Alonso-Casado O; Torres-Mesa P; Guiñez G; Gonzalez-Moreno S
Clin Transl Oncol; 2018 Oct; 20(10):1268-1273. PubMed ID: 29667123
[TBL] [Abstract][Full Text] [Related]
18. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for colorectal and appendiceal peritoneal metastases - The Hong Kong experience and literature review.
Chow FC; Yip J; Foo DC; Wei R; Choi HK; Ng KK; Lo OS
Asian J Surg; 2021 Jan; 44(1):221-228. PubMed ID: 32605790
[TBL] [Abstract][Full Text] [Related]
19. Preoperative neutrophil-to-lymphocyte ratio is a more valuable prognostic factor than platelet-to-lymphocyte ratio for nonmetastatic rectal cancer.
Li H; Song J; Cao M; Wang G; Li L; Zhang B; Li Y; Xu W; Zheng J
Int Immunopharmacol; 2016 Nov; 40():327-331. PubMed ID: 27664571
[TBL] [Abstract][Full Text] [Related]
20. The absence of benefit of perioperative chemotherapy in initially resectable peritoneal metastases of colorectal cancer origin treated with complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: A retrospective analysis.
Repullo DJ; Barbois S; Leonard D; Bohlok A; Van den Audenaeren ET; Hendlisz A; Van den Eynde M; Donckier V; Kartheuser A; Liberale G
Eur J Surg Oncol; 2021 Jul; 47(7):1661-1667. PubMed ID: 33602530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
